Soleno Therapeutics (SLNO) has seen its stock price swing in recent weeks, catching the attention of investors looking for value and momentum. The company focuses on treatments for rare diseases, which often draws keen interest from the biotech community.

See our latest analysis for Soleno Therapeutics.

Soleno’s share price has been on a volatile run lately, with strong short-term swings: up nearly 12% for the week, but still down around 25% over the past three months. Despite recent turbulence, the company’s long-term performance truly stands out, with a staggering 4,846% total shareholder return over three years and a remarkable 74% over five years. This highlights the potential for biotech momentum to accelerate quickly as sentiment shifts.

Curious about what other promising healthcare names could be building steam? It might be the perfect time to explore fresh opportunities with our See the full list for free.

Given such explosive historical returns but steep recent drops, is Soleno Therapeutics now flying under the radar at a bargain price, or is the market already factoring in all the company’s future growth prospects?

With its current price-to-sales ratio standing at 27.5x, Soleno Therapeutics trades at a hefty premium versus peers. This suggests the market is pricing in significant future growth.

The price-to-sales (P/S) ratio measures the value investors are placing on each dollar of the company’s sales and is commonly used for companies that do not yet generate profits, like many in the biotech sector. A higher ratio can indicate robust growth expectations, but it also suggests the stock price could be vulnerable if those expectations are not met.

In Soleno’s case, the P/S ratio is well above both the U.S. biotech industry average of 12.8x and the peer average of 22.5x. This signals investors see Soleno’s future as much brighter than its competitors. However, it is also trading above the estimated fair price-to-sales ratio of 21.4x, a level the market could recalibrate toward if growth stumbles.

Explore the SWS fair ratio for Soleno Therapeutics

Result: Price-to-Sales of 27.5x (OVERVALUED)

However, strong revenue growth alone cannot guarantee future gains. Setbacks in clinical trials or regulatory challenges could swiftly reverse positive sentiment.

Find out about the key risks to this Soleno Therapeutics narrative.

While Soleno’s price-to-sales ratio appears steep, our DCF model presents a different perspective. Based on projected future cash flows, the SWS DCF model estimates the fair value at $431.02, making the current share price of $50.45 appear significantly undervalued. The question remains whether the market is underestimating Soleno’s potential or if risks continue to outweigh the possible rewards.